<DOC>
	<DOCNO>NCT00077727</DOCNO>
	<brief_summary>The purpose study determine add extended-release galantamine hydrobromide , compare add placebo , current atypical antipsychotic therapy well tolerate effective improve cognitive impairment patient schizophrenia .</brief_summary>
	<brief_title>A Study Effectiveness Safety Galantamine Hydrobromide Cognitive Impairment Patients With Schizophrenia .</brief_title>
	<detailed_description>Galantamine act acetylcholinesterase , show effectively treat cognitive symptom patient Alzheimer 's disease . Previous cellular research nicotinic receptor show promising result , theorize nicotinic system patient schizophrenia may abnormal may play important role cognitive symptom associate schizophrenia . It also postulate galantamine may improve neuropsychiatric symptom hallucination , delusion , apathy patient Alzheimer 's disease . Atypical antipsychotic medication effective treatment schizophrenia patient symptom remain . Therefore , galantamine may useful cotreatment schizophrenia patient atypical antipsychotic treatment . This pilot dose-ranging , randomize ( patient assign different treatment base chance ) , double-blind ( neither patient physician know whether drug placebo take , dosage ) , placebo-controlled multicenter study examine effect take extended-release galantamine hydrobromide ( 16 24 mg daily ) placebo effectiveness reduce symptom schizophrenia patient already take atypical antipsychotic medication . The safety combine treatment also examine . Measures effectiveness include Positive Negative Syndrome Scale ( PANSS ) measure neuropsychiatric symptom schizophrenia ; Clinical Global Impression ( CGI ) scale measure change course study ; Brief Assessment Cognition Schizophrenia ( BACS ) verbal memory learning , work memory , motor function , attention , verbal fluency , executive functioning ; Continuous Performance Test ( CPT ) sustain attention distractability ; reaction time test ( RTT ) finger tap test ( FTT ) psychomotor speed ; Lexical Semantic Fluency Test ( LSFT ) language skill . As schizophrenia patient population high nicotine use , galantamine may act nicotine receptor , blood level nicotine also measure vary nicotine level could alter effect galantamine . The null hypothesis difference 2 group ( galantamine cotreatment placebo ) test efficacy measurement ( total PANSS , BACS , CGI score ) Week 8 . Measures safety include physical examination , electrocardiogram ( ECGs ) , clinical laboratory test , measurement plasma prolactin concentration , pregnancy test woman , incidence adverse event . Adverse event might relate medication also monitor use Simpson-Angus Extrapyramidal Side Effects Scale ( SAS ) , Barnes Akathisia Rating Scale ( BARS ) , Abnormal Involuntary Movement Scale ( AIMS ) . Extended-release galantamine hydrobromide match placebo capsule once-daily dose . Patients take 8 milligram ( mg ) per day Week 1 , 16 mg per day Week 2 , 16 mg 24 mg per day ( depend randomization ) Weeks 3 8 . Treatment group placebo capsule , 16 mg capsule , 24 mg capsule .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis schizophrenia present least 1 year , return his/her level function disease , Brief Psychiatric Rating Scale score 30 60 ( inclusive ) , cognitive impairment determine score neuropsychological test subtests Nicotine user minimum intake equivalent 5 cigarette per day On stable dose allow atypical antipsychotic medication ( risperidone [ either oral CONSTA ] , olanzapine , quetiapine , ziprasidone , aripiprazole ) alone combination , least 30 day screen , deem able continue dose Women patient must postmenopausal , surgically sterile , use appropriate contraception entry throughout study , negative pregnancy test screen Able read , write , understand English , limitation communication skill would prevent him/her complete cognitive test use study . Previously enrol galantamine hydrobromide study Any clinically significant uncontrolled medical illness ( peptic ulcer disease urinary tract obstruction neurologic , cardiac , hepatic , renal , metabolic , endocrine disturbance ) History severe asthma Any history epilepsy convulsion , except febrile convulsion childhood History cancer within past year , except treat basal cell carcinoma , history prolactindependent breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>cognitive impairment</keyword>
	<keyword>galantamine</keyword>
	<keyword>acetylcholinesterase inhibitor</keyword>
	<keyword>antipsychotic drug</keyword>
	<keyword>BACS</keyword>
</DOC>